宫内SSRI暴露与新生儿产房复苏需求相关
这项回顾性队列研究纳入4933名足月单胎新生儿,其中3.3%存在宫内SSRI暴露(定义为孕晚期母体SSRI治疗记录)。暴露组产房呼吸支持启动率显著高于非暴露组(12.9% vs 4.2%,校正OR 4.04,95%CI 2.40-6.49),NICU入住率和1分钟Apgar评分≤5的比例也更高。结论提示孕晚期SSRI暴露应被视为需要复苏的风险因素,但机制未明且不能假定因果关系。
要点
- 足月儿宫内SSRI暴露者产房呼吸支持启动率12.9%,非暴露者4.2%。
- 暴露组NICU入住校正OR 2.19(95%CI 1.30-3.50)。
- 孕晚期SSRI暴露可视为产房复苏需求的危险因素。
核心结论
- 在该队列中,宫内SSRI暴露与产房复苏及NICU入住的 odds 显著增加相关。
- 机制尚未确定,不能假定因果关系,但研究结果支持将孕晚期SSRI暴露视为需要复苏的风险因素。
研究设计与样本
- 回顾性队列研究,数据来自芝加哥西北医学医院病历记录。
- 纳入6个月期间4933名足月单胎新生儿,排除重大先天畸形。
- 宫内SSRI暴露定义为孕晚期母体SSRI治疗记录,暴露率3.3%。
- 主要结局为按新生儿复苏项目算法启动产房呼吸支持。
主要发现
- SSRI暴露组产房呼吸支持启动率为12.9%,非暴露组为4.2%,校正OR 4.04(95%CI 2.40-6.49)。
- SSRI暴露与NICU入住率升高相关,校正OR 2.19(95%CI 1.30-3.50)。
- SSRI暴露与1分钟Apgar评分≤5相关,校正OR 3.51(95%CI 2.07-5.67)。
关键数值与推荐
- 宫内SSRI暴露定义为孕晚期母体SSRI治疗记录。
- 主要结局指标为按新生儿复苏项目算法启动产房呼吸支持。
- SSRI暴露组产房呼吸支持启动率12.9%,非暴露组4.2%。
- 校正OR 4.04(95%CI 2.40-6.49)对应产房呼吸支持启动。
- 校正OR 2.19(95%CI 1.30-3.50)对应NICU入住,校正OR 3.51(95%CI 2.07-5.67)对应1分钟Apgar≤5。
临床怎么用
- 对孕晚期有SSRI暴露史的足月新生儿,产房团队应提前做好呼吸支持准备。
- 可将孕晚期SSRI暴露纳入产房复苏风险评估,但需结合个体情况。
- 暴露新生儿出生后应加强呼吸监测,警惕NICU入住需求。
局限性
- 回顾性队列设计,不能确定因果关系。
- 机制 underlying 这些关联尚未确定。
- 暴露定义依赖病历记录中的孕晚期母体SSRI治疗文档。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether full-term neonates with in utero exposure to selective serotonin reuptake inhibitors (SSRI) require respiratory support in the delivery room, as indicated by the standardized Neonatal Resuscitation Program algorithm, significantly more often than nonexposed neonates. STUDY DESIGN: In this retrospective cohort study, we extracted data from medical records of full-term neonates with and without in utero SSRI exposure, defined as documentation of third trimester maternal SSRI treatment. A hospital-based sample was identified at Northwestern Medical Hospital in Chicago, Illinois. Full-term singleton newborns identified in a 6-month period (n = 4933) were selected for study. Neonates with a major congenital anomaly were excluded. The primary outcome was initiation of respiratory support in the delivery room, as indicated by the Neonatal Resuscitation Program algorithm. RESULTS: Of the 4933 full-term singleton neonates, 3.3% were exposed to SSRI in utero. Respiratory support was initiated significantly more often in SSRI exposed (12.9%) than unexposed (4.2%) neonates (covariate-adjusted OR, 4.04; 95% CI, 2.40-6.49). In utero SSRI exposure also was associated with a higher rate of neonatal intensive care unit admission (covariate-adjusted OR, 2.19; 95% CI, 1.30-3.50) and 1-minute Apgar score of ≤5 (covariate-adjusted OR, 3.51; 95% CI, 2.07-5.67). CONCLUSIONS: In this cohort, in utero SSRI exposure was associated with a significantly greater odds of resuscitation in the delivery room as well as neonatal intensive care unit admission. Although the mechanism underlying these associations have not been determined and causality cannot be assumed, these findings support a recommendation that third trimester SSRI exposure be considered a risk factor for needing resuscitation.
引用
- Ulbrich KA, Zumpf K, Ciolino JD, et al. Acute Delivery Room Resuscitation of Neonates Exposed to Selective Serotonin Reuptake Inhibitors. J Pediatr. 2021. PMID: 33453205. doi:10.1016/j.jpeds.2021.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。